Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in Stendörren Fastigheter AB (publ):s issuance and repurchase of bonds
Mandate

Vinge advises in Stendörren Fastigheter AB (publ):s issuance and repurchase of bonds

January 22, 2021 Banking and Finance

Vinge advises in Stendörren’s issuance of a new senior unsecured bond in an amount of SEK 700,000,000 within a framework amount of SEK 1,000,000,000 and in Stendörren’s repurchase of its existing senior unsecured bonds.

The new bonds have a tenor of 3.25 years and carries a floating rate interest of 3 months STIBOR plus 365 basis points. In accordance with the terms and conditions, the new bonds are intended to be listed on the corporate bond list of Nasdaq Stockholm. Nordea Bank Abp and Swedbank AB (publ) acted as arrangers, bookrunners and dealer managers in connection with the transaction. Swedbank AB (publ) also acted as issuing agent.

Vinge’s team consisted of Louise Brorsson Salomon, Lionardo Ojeda and Hannes Pettersson.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026